Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in ChinaYuankai Shi, Jingwen Wang, Zhengming Jin et al.|Journal of Hematology & Oncology|2017Cited by 256
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trialYuankai Shi, Peng Liu, Hang Su et al.|The Lancet Haematology|2019Cited by 248
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimabYuankai Shi, Bo Peng, Hang Su et al.|EBioMedicine|2020Cited by 41
Synergistic Killing Effect between Vorinostat and Target of CD146 in Malignant CellsXiaoli Ma, Jianfeng Zhou|Clinical Cancer Research|2010Cited by 15
Development and functional characterization of novel fully human anti‐CD19 chimeric antigen receptors for T‐cell therapyZhenyu Dai, Jianfeng Zhou|Journal of Cellular Physiology|2021Cited by 7